COVID19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: 3 Tabs Tranilast ( TAIYO ) from Takeda Pharmaceutical, daily until 7 days. Both intervention and control groups will be received routine drugs. Intervention 2: Con
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Age =18 years Laboratory polymerase chain reaction (PCR) confirmed infection with COVID19 Lung involvement confirmed with chest imaging Hospitalized with: Fever Or Cough Less than 8 days since illness onset Willingness of study participant to accept randomization to any assigned treatment arm Acceptance of non-participation in another study before the 28th day of the study arterial blood O2 saturation under 93% non-pregnant females
Exclusion criteria
Exclusion criteria: Autoimmune diseases (lupus, MS, etc.) Hepatic failure Hepatit B, C, pregnant and lactating women use of antioxidants, anti-inflammatory and immunosuppressant drugs kidney failure known allergy to Tranilast
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ICU-admitted patients. Timepoint: after treatment. Method of measurement: Record information in a checklist by a trained nurse.;Duration of ICU-admission. Timepoint: after treatment. Method of measurement: Record information in a checklist by a trained nurse.;Deaths. Timepoint: After the intervention until the 28th day. Method of measurement: Record information in a checklist by a trained nurse.;Neutrophil-lymphocyte ratio (NLR). Timepoint: End of day 7. Method of measurement: White blood cell count.;C-reactive protein. Timepoint: End of day 7. Method of measurement: ELISA. | — |
Secondary
| Measure | Time frame |
|---|---|
| IL1. Timepoint: Before and 7 days after starting treatment. Method of measurement: ELISA (enzyme-linked immunosorbent assay).;IL6. Timepoint: Before and 7 days after starting treatment. Method of measurement: ELISA (enzyme-linked immunosorbent assay).;CBC. Timepoint: Before and 7 days after starting treatment. Method of measurement: Cell Counter.;TNF. Timepoint: Before and 7 days after starting treatment. Method of measurement: ELISA (enzyme-linked immunosorbent assay).;D-dimer. Timepoint: Before and 7 days after starting treatment. Method of measurement: ELISA (enzyme-linked immunosorbent assay).;SGPT. Timepoint: Baseline and days 7. Method of measurement: blood biochimecal test.;SGOT. Timepoint: Baseline and days 7. Method of measurement: blood biochimecal test.;Blood oxygen saturation percentage. Timepoint: Before and ten days after starting treatment. Method of measurement: Pulse oximeter. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli khodadadi
Ahvaz University of Medical Sciences
Outcome results
None listed